Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression
A Randomized Blinded Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation of Left Prefrontal Cortex in Patients With Treatment-resistant Depression
2 other identifiers
interventional
3
1 country
1
Brief Summary
Major depressive disorder (MDD) is a significant public health problem. Existing treatment modalities are not always sufficient to alleviate this disorder. Treatment refractoriness is a common clinical problem. Transcranial direct current stimulation (t-DCS), a non-invasive brain stimulation technique, has been shown to be effective in alleviating depressive symptoms in preliminary studies. There is need to explore the role of t-DCS in Treatment-resistant depression (TRD). Therefore, the investigators aim to undertake this exploratory study. Aim: Compare the role of left prefrontal cortex anodal t-DCS daily stimulation of 4 weeks (20 week days) with sham stimulation in alleviating depressive symptoms in patients with TRD. Methodology: Patients who seek treatment in our treatment resistant depression clinic and who have failed to respond to treatment with two antidepressant medications will be offered to enroll in this study. The aim is to study 20 patients who meet the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for MDD between the ages of 21-65 years. Those subjects that receive sham stimulation will be offered to have active t-DCS stimulation for additional 3 weeks to get any benefit that they may have otherwise missed by being in the sham stimulation group. Results and Conclusions: The investigators will compare the mean baseline and end of treatment Montgomery Asberg depression rating scale between the two groups. The investigators will compare the change in mean depression scores between the baseline and end of treatment in those receiving active t-DCS for a total of 7 weeks duration. This study is innovative and of significance in exploring the role of this novel, easy to administer, safe and cost effective treatment modality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4 major-depressive-disorder
Started May 2014
Typical duration for phase_4 major-depressive-disorder
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 15, 2014
CompletedFirst Posted
Study publicly available on registry
May 19, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 8, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 8, 2018
CompletedJanuary 12, 2018
January 1, 2018
3.7 years
May 15, 2014
January 10, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Montgomery Asberg depression rating scale score
Investigators will measure the changes in Montgomery Asberg depression rating scale scores with trans-cranial direct current stimulation
6 months
Study Arms (2)
Sham Controlled Arm
SHAM COMPARATORThe subjects randomized to this group will not receive stimulation daily for four weeks.
Transcranial direct current stimulation (t-DCS)
ACTIVE COMPARATORThe subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
Interventions
The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
The subjects randomized to this group will not receive stimulation daily for four weeks.
Eligibility Criteria
You may qualify if:
- Subjects that meet criteria for Major depressive disorder (MDD)
- ages 21 to 65 years and
- who are treatment resistant
You may not qualify if:
- Co-morbid substance abuse in last one month.
- Psychotropic medication changes in last two weeks.
- Unstable medical or psychiatric problems that need intensive outpatient or inpatient treatment
- Patients who are not competent to consent for the study
- Urine pregnancy test positive
- Ferromagnetic Implanted devices that use electrical or magnetic currents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Univ of Florida
Gainesville, Florida, 32606, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Khurshid Khurshid, M.D
University of Florida
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2014
First Posted
May 19, 2014
Study Start
May 1, 2014
Primary Completion
January 8, 2018
Study Completion
January 8, 2018
Last Updated
January 12, 2018
Record last verified: 2018-01